Vaccinogen Inc (VGEN) 0.9800 $VGEN
Vaccinogen Believes That Its "Whole-Tumor Methodology" and Focus on "Cancer Heterogeneity" is Supported by Research Published in The Proceedings of the National Academy of Sciences (PNAS)
PR Newswire - Wed Dec 02, 6:33AM CST
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, believes that an article published in The Proceedings of the National Academy of Sciences (PNAS) strongly supports the central thesis for the Company's OncoVAX® cancer immunotherapy platform and its whole-tumor methodology.
Vaccinogen Promotes Peter Morsing, Ph.D. to Chief Operating Officer
PR Newswire - Wed Nov 04, 6:33AM CST
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced the promotion of Peter Morsing, Ph.D., to the position of Chief Operating Officer (COO). Dr. Morsing previously served as Vaccinogen's Global Head of Business Development & Strategy and is one of five Ph.D.'s that has joined the senior ranks of Vaccinogen in the last 13 months.
Vaccinogen Engages D. Barry Boyd, M.D., M.S., as Senior Oncology Advisor
PR Newswire - Wed Oct 28, 6:33AM CDT
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced the engagement of D. Barry Boyd, M.D., M.S., to the newly established position of Senior Oncology Advisor and his appointment to the Company's Medical Advisory Board. Dr. Boyd is a specialist in the treatment of cancer and will provide expert counsel to Vaccinogen as the company pursues its ACTIVE Phase IIIb OncoVAX® clinical trial and expands its human antibody program (HuMabs).
Vaccinogen Appoints Michael G. Hagerman to its Board of Directors
PR Newswire - Tue Oct 06, 6:33AM CDT
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced the appointment of Michael G. Hagerman, Cofounder and Partner of ACT Medical Solutions Inc. to its Board of Directors.
Vaccinogen Enhances Patient-Derived Antibody Program with Revolutionary High-Throughput Single Cell Screening and Analysis System
PR Newswire - Wed Sep 09, 6:33AM CDT
Vaccinogen, Inc. ("Vaccinogen"
(OTC.QB: VGEN), a cancer immunotherapy development company, announced today it has entered into an exclusive option agreement with Dublin City University (DCU), through one of its subsidiaries, that provides the Company with an exclusive two-year option to evaluate and acquire a revolutionary high-throughput, multiplex, analysis platform - DiCAST. In conjunction with the agreement, the scientific team that developed DiCAST, including the lead inventor, Dr. Paul Leonard, has joined Vaccinogen and will spearhead the Company's operations in Ireland, a critical component of its global translational research strategy.
Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board
PR Newswire - Tue May 05, 6:00AM CDT
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced that its Board of Directors has unanimously elected Co-founder, President, Chief Executive Officer and current Director, Andrew L. Tussing, to the role of Chairman of the Board. Mr. Tussing replaces Benjamin S. Carson, Sr., MD, who resigned from the Board and his role as Chairman and a member of Vaccinogen's Medical Advisory Board role to pursue his candidacy for the President of the United States via the Republican nomination.
Vaccinogen Elects Ronald Kaiser to Board of Directors
PR Newswire - Tue Feb 17, 6:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leading cancer immunotherapy company, announced today that Ronald W. Kaiser, a biotech executive leader with more than 35 years of financial and accounting expertise, has been elected to the company's Board of Directors. Mr. Kaiser will also chair the company's Audit Committee and serve on the company's Nominating and Corporate Governance Committees.
Vaccinogen Names Dr. Peter Morsing as Head of Business Development
PR Newswire - Mon Jan 12, 8:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leader in cancer immunotherapy development, announced today that Peter Morsing, Ph.D., a 20-year pharmaceutical industry veteran, has joined the company as Head of Business Development.
Vaccinogen Believes That Its "Whole-Tumor Methodology" and Focus on "Cancer Heterogeneity" is Supported by Research Published in The Proceedings of the National Academy of Sciences (PNAS)
PR Newswire - Wed Dec 02, 6:33AM CST
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, believes that an article published in The Proceedings of the National Academy of Sciences (PNAS) strongly supports the central thesis for the Company's OncoVAX® cancer immunotherapy platform and its whole-tumor methodology.
Vaccinogen Promotes Peter Morsing, Ph.D. to Chief Operating Officer
PR Newswire - Wed Nov 04, 6:33AM CST
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced the promotion of Peter Morsing, Ph.D., to the position of Chief Operating Officer (COO). Dr. Morsing previously served as Vaccinogen's Global Head of Business Development & Strategy and is one of five Ph.D.'s that has joined the senior ranks of Vaccinogen in the last 13 months.
Vaccinogen Engages D. Barry Boyd, M.D., M.S., as Senior Oncology Advisor
PR Newswire - Wed Oct 28, 6:33AM CDT
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced the engagement of D. Barry Boyd, M.D., M.S., to the newly established position of Senior Oncology Advisor and his appointment to the Company's Medical Advisory Board. Dr. Boyd is a specialist in the treatment of cancer and will provide expert counsel to Vaccinogen as the company pursues its ACTIVE Phase IIIb OncoVAX® clinical trial and expands its human antibody program (HuMabs).
Vaccinogen Appoints Michael G. Hagerman to its Board of Directors
PR Newswire - Tue Oct 06, 6:33AM CDT
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced the appointment of Michael G. Hagerman, Cofounder and Partner of ACT Medical Solutions Inc. to its Board of Directors.
Vaccinogen Enhances Patient-Derived Antibody Program with Revolutionary High-Throughput Single Cell Screening and Analysis System
PR Newswire - Wed Sep 09, 6:33AM CDT
Vaccinogen, Inc. ("Vaccinogen"
(OTC.QB: VGEN), a cancer immunotherapy development company, announced today it has entered into an exclusive option agreement with Dublin City University (DCU), through one of its subsidiaries, that provides the Company with an exclusive two-year option to evaluate and acquire a revolutionary high-throughput, multiplex, analysis platform - DiCAST. In conjunction with the agreement, the scientific team that developed DiCAST, including the lead inventor, Dr. Paul Leonard, has joined Vaccinogen and will spearhead the Company's operations in Ireland, a critical component of its global translational research strategy. Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board
PR Newswire - Tue May 05, 6:00AM CDT
Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced that its Board of Directors has unanimously elected Co-founder, President, Chief Executive Officer and current Director, Andrew L. Tussing, to the role of Chairman of the Board. Mr. Tussing replaces Benjamin S. Carson, Sr., MD, who resigned from the Board and his role as Chairman and a member of Vaccinogen's Medical Advisory Board role to pursue his candidacy for the President of the United States via the Republican nomination.
Vaccinogen Elects Ronald Kaiser to Board of Directors
PR Newswire - Tue Feb 17, 6:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leading cancer immunotherapy company, announced today that Ronald W. Kaiser, a biotech executive leader with more than 35 years of financial and accounting expertise, has been elected to the company's Board of Directors. Mr. Kaiser will also chair the company's Audit Committee and serve on the company's Nominating and Corporate Governance Committees.
Vaccinogen Names Dr. Peter Morsing as Head of Business Development
PR Newswire - Mon Jan 12, 8:00AM CST
Vaccinogen, Inc., (OTC.QB: VGEN) a leader in cancer immunotherapy development, announced today that Peter Morsing, Ph.D., a 20-year pharmaceutical industry veteran, has joined the company as Head of Business Development.
